Publications by authors named "Borislav Borissov"

Claim this Profile
C
Cost-Effectiveness Analysis of Innovative Therapies for Patients with Non-Alcoholic Fatty Liver Disease.
Michal Pochopien, Jakub Wladyslaw Dziedzic, Samuel Aballea, Emilie Clay, Iwona Zerda, Borislav Borissov

J Mark Access Health Policy· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.
Tingting Qiu, Shuyao Liang, Yitong Wang, Claude Dussart, Borislav Borissov

Front Public Health· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene therapy randomised clinical trials in Europe - a review paper of methodology and design.
Krassimira Ilieva, Borislav Borissov, Mondher Toumi

J Mark Access Health Policy· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why "American Patients First" is likely to raise drug prices outside of the United States.
Monique Dabbous, Cyprien Milea, Steven Simoens, Clement François, Claude Dussart, Borislav Borissov

J Mark Access Health Policy· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcome claims in European and United States orphan drug approvals.
Szymon Jarosławski, Pascal Auquier, Borislav Borissov, Claude Dussart, Mondher Toumi

J Mark Access Health Policy· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration.
Szymon Jarosławski, Pascal Auquier, Borislav Borissov, Claude Dussart, Mondher Toumi

J Mark Access Health Policy· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years.
Borislav Borissov, Michael Urbich, Boryana Georgieva, Svetoslav Tsenov, Guillermo Villa

J Mark Access Health Policy· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis